Opinion|Videos|January 12, 2024
Strategies for Managing Treatment-Naïve CLL with High-Risk Features
Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC
5